arrow
S

Sara A. Healy

national institutes of health
H指数:25
被引数:3,283

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial
2025-06-030
OAAI
Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
2024-12-014
PRE
Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria
2024-05-029
OA
Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1 randomised, controlled trial
2023-11-0117
PRE
Sporozoite immunization: innovative translational science to support the fight against malaria

子孢子预防接种: 支持抗击疟疾的创新转化科学

2023-08-1122
OAAI
Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali
2022-11-1745
OA
A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes (vol 12, 1750, 2021)
2022-08-150
OAAI
Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial
2022-03-0150
OAAI
Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity
Nature
IF48.5
2021-06-300
PREAI
Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice
2021-04-0165
OAAI
Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults
2019-10-1710
OAAI
Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults
2018-09-0190
OAAI